Pipeline Therapeutics announced the initiation of their Phase 1 clinical trial for PIPE-307, a drug targeting remyelination. At the bottom of the press release under their About, they state that they're still currently enrolling for their PIPE-505 Phase 1/2 which seems kinda... weird? Based on...